David Lebowitz
Stock Analyst at Citigroup
(3.90)
# 637
Out of 4,983 analysts
119
Total ratings
59.77%
Success rate
7.69%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $61.32 | +37.00% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $49.76 | +68.81% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $24.58 | +95.28% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $19.11 | +4.66% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $197.24 | +47.03% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $83.90 | +22.77% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $23.69 | +60.41% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $12.54 | +75.44% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $51.49 | +30.12% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $39.14 | +43.08% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $12.27 | -18.50% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.53 | -1.96% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $59.69 | -24.61% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $73.79 | -7.85% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $427.05 | -10.55% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $53.94 | +77.98% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $8.31 | +44.40% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $461.24 | -64.44% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $16.97 | +129.82% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $15.04 | +39.63% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.26 | +6,369.65% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.30 | +976.92% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $61.32
Upside: +37.00%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $49.76
Upside: +68.81%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $24.58
Upside: +95.28%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $19.11
Upside: +4.66%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $197.24
Upside: +47.03%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $83.90
Upside: +22.77%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $23.69
Upside: +60.41%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $12.54
Upside: +75.44%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $51.49
Upside: +30.12%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $39.14
Upside: +43.08%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $12.27
Upside: -18.50%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.53
Upside: -1.96%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $59.69
Upside: -24.61%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $73.79
Upside: -7.85%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $427.05
Upside: -10.55%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $53.94
Upside: +77.98%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $8.31
Upside: +44.40%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $461.24
Upside: -64.44%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $16.97
Upside: +129.82%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $15.04
Upside: +39.63%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.26
Upside: +6,369.65%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.30
Upside: +976.92%